Market Performance Analysis of Hexu China (603122.SH) After 13 Limit-Up Days in 15 Trading Sessions
Unlock More Features
Login to access AI-powered analysis, deep research reports and more advanced features
About us: Ginlix AI is the AI Investment Copilot powered by real data, bridging advanced AI with professional financial databases to provide verifiable, truth-based answers. Please use the chat box below to ask any financial question.
Related Stocks
Hexu China (603122.SH) declined after gaining 13 limit-up days in 15 trading sessions, attracting widespread market attention [1][2].
Analysts pointed out that the stock’s rise was mainly driven by irrational market speculation and thematic concepts, including the Fujian sector hotspot, pharmaceutical commerce concept, etc. [0].
The company’s fundamentals are weak: net profit in Q3 2025 was a loss of 5.0479 million yuan, and revenue from January to September decreased by 22.80% year-on-year [0]. In terms of valuation, its price-to-earnings ratio is as high as 343.67 times, far exceeding the industry average of 29 times [0].
The Shanghai Stock Exchange has placed the stock under key monitoring and suspended trading for verification multiple times [0]. The company clearly responded that there is no additional positive information and no undisclosed information that should be disclosed [0].
Recently, the stock has declined, and market concerns about its high valuation and regulatory risks have intensified [3].
Insights are generated using AI models and historical data for informational purposes only. They do not constitute investment advice or recommendations. Past performance is not indicative of future results.
About us: Ginlix AI is the AI Investment Copilot powered by real data, bridging advanced AI with professional financial databases to provide verifiable, truth-based answers. Please use the chat box below to ask any financial question.